Hepatitis C Infection and Nonalcoholic Fatty Liver Disease

Clinics in Liver Disease

Volumn 12, Issue 3, 2008, Pages 573-585

  Cheung, Onpan ^a   Sanyal, Arun J ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIVIRUS AGENT; FLUINDOSTATIN; GAMMA INTERFERON; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PIOGLITAZONE;

AFRICAN AMERICAN; ANTIVIRAL THERAPY; DRUG ACTIVITY; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; NONALCOHOLIC FATTY LIVER; NORTH AMERICA; REVIEW; RISK FACTOR; UNITED STATES; VIRUS REPLICATION;

DISEASE PROGRESSION; FATTY LIVER; HEPATITIS C, CHRONIC; HUMANS; RISK FACTORS;

EID: 46749149198     PISSN: 10893261     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cld.2008.03.005     Document Type: Review

References (84)

1. WHO VHPB. Global surveillance and control of hepatitis C. J Viral Hepat 6 (1999) 35-47
2. Alter M.J., Kruszon-Moran D., Nainan O.V., et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 341 (1999) 556-562
3. Kim W.R., Brown Jr. R.S., Terrault N.A., et al. Burden of liver disease in the United States: summary of a workshop. Hepatology 36 (2002) 227-242
4. Browning J.D., Szczepaniak L.S., Dobbins R., et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 40 (2004) 1387-1395
5. Ekstedt M., Franzen L.E., Mathiesen U.L., et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 44 (2006) 865-873
6. Kleiner D.E., Brunt E.M., Van Natta M., et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41 (2005) 1313-1321
7. Beymer C., Kowdley K.V., Larson A., et al. Prevalence and predictors of asymptomatic liver disease in patients undergoing gastric bypass surgery. Arch Surg 138 (2003) 1240-1244
8. Spaulding L., Trainer T., and Janiec D. Prevalence of non-alcoholic steatohepatitis in morbidly obese subjects undergoing gastric bypass. Obes Surg 13 (2003) 347-349
9. Giday S.A., Ashiny Z., Naab T., et al. Frequency of nonalcoholic fatty liver disease and degree of hepatic steatosis in African-American patients. J Natl Med Assoc 98 (2006) 1613-1615
10. Marchesini G., Brizi M., Bianchi G., et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 50 (2001) 1844-1850
11. Marchesini G., Bugianesi E., Forlani G., et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 37 (2003) 917-923
12. Reddy J.K., and Rao M.S. Lipid metabolism and liver inflammation. II. Fatty liver disease and fatty acid oxidation. Am J Physiol Gastrointest Liver Physiol 290 (2006) G852-G858
13. Puri P., Baillie R.A., Wiest M.M., et al. A lipidomic analysis of nonalcoholic fatty liver disease. Hepatology (2007) in press
14. Araya J., Rodrigo R., Videla L.A., et al. Increase in long-chain polyunsaturated fatty acid n - 6/n - 3 ratio in relation to hepatic steatosis in patients with non-alcoholic fatty liver disease. Clin Sci (Lond) 106 (2004) 635-643
15. Boden G. Free fatty acids (FFA), a link between obesity and insulin resistance. Front Biosci 3 (1998) d169-d175
16. Thompson A.L., Lim-Fraser M.Y., Kraegen E.W., et al. Effects of individual fatty acids on glucose uptake and glycogen synthesis in soleus muscle in vitro. Am J Physiol Endocrinol Metab 279 (2000) E577-E584
17. Kim J.K., Fillmore J.J., Chen Y., et al. Tissue-specific overexpression of lipoprotein lipase causes tissue-specific insulin resistance. Proc Natl Acad Sci U S A 98 (2001) 7522-7527
18. Browning J.D., and Horton J.D. Molecular mediators of hepatic steatosis and liver injury. J Clin Invest 114 (2004) 147-152
19. Adams L.A., Angulo P., and Lindor K.D. Nonalcoholic fatty liver disease. Cmaj 172 (2005) 899-905
20. Evans R.M., Barish G.D., and Wang Y.X. PPARs and the complex journey to obesity. Nat Med 10 (2004) 355-361
21. Hashimoto T., Cook W.S., Qi C., et al. Defect in peroxisome proliferator-activated receptor alpha-inducible fatty acid oxidation determines the severity of hepatic steatosis in response to fasting. J Biol Chem 275 (2000) 28918-28928
22. Goodman Z.D., and Ishak K.G. Histopathology of hepatitis C virus infection. Semin Liver Dis 15 (1995) 70-81
23. Rubbia-Brandt L., Quadri R., Abid K., et al. Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3. J Hepatol 33 (2000) 106-115
24. Lonardo A., Adinolfi L.E., Loria P., et al. Steatosis and hepatitis C virus: mechanisms and significance for hepatic and extrahepatic disease. Gastroenterology 126 (2004) 586-597
25. Monto A., Alonzo J., Watson J.J., et al. Steatosis in chronic hepatitis C: relative contributions of obesity, diabetes mellitus, and alcohol. Hepatology 36 (2002) 729-736
26. Rubbia-Brandt L., Fabris P., Paganin S., et al. Steatosis affects chronic hepatitis C progression in a genotype specific way. Gut 53 (2004) 406-412
27. Castera L., Hezode C., Roudot-Thoraval F., et al. Effect of antiviral treatment on evolution of liver steatosis in patients with chronic hepatitis C: indirect evidence of a role of hepatitis C virus genotype 3 in steatosis. Gut 53 (2004) 420-424
28. Hezode C., Roudot-Thoraval F., Zafrani E.S., et al. Different mechanisms of steatosis in hepatitis C virus genotypes 1 and 3 infections. J Viral Hepat 11 (2004) 455-458
29. Patton H.M., Patel K., Behling C., et al. The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients. J Hepatol 40 (2004) 484-490
30. Barba G., Harper F., Harada T., et al. Hepatitis C virus core protein shows a cytoplasmic localization and associates to cellular lipid storage droplets. Proc Natl Acad Sci U S A 94 (1997) 1200-1205
31. Moradpour D., Englert C., Wakita T., et al. Characterization of cell lines allowing tightly regulated expression of hepatitis C virus core protein. Virology 222 (1996) 51-63
32. Waris G., Felmlee D.J., Negro F., et al. Hepatitis C virus induces the proteolytic cleavage of sterol regulatory element binding proteins (SREBPs) and stimulates the phosphorylation of SREBPs via oxidative stress. J Virol 81 15 (2007) 8122-8130
33. Tsochatzis E., Papatheodoridis G.V., Manesis E.K., et al. Hepatic steatosis in genotype 4 chronic hepatitis C is mainly because of metabolic factors. Am J Gastroenterol 102 (2007) 634-641
34. Hui J.M., Sud A., Farrell G.C., et al. Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression. [corrected]. Gastroenterology 125 (2003) 1695-1704
35. McCaughan G.W., and George J. Fibrosis progression in chronic hepatitis C virus infection. Gut 53 (2004) 318-321
36. Aytug S., Reich D., Sapiro L.E., et al. Impaired IRS-1/PI3-kinase signaling in patients with HCV: a mechanism for increased prevalence of type 2 diabetes. Hepatology 38 (2003) 1384-1392
37. Kawaguchi T., Ide T., Taniguchi E., et al. Clearance of HCV improves insulin resistance, beta-cell function, and hepatic expression of insulin receptor substrate 1 and 2. Am J Gastroenterol 102 (2007) 570-576
38. Shintani Y., Fujie H., Miyoshi H., et al. Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance. Gastroenterology 126 (2004) 840-848
39. Halse R., Pearson S.L., McCormack J.G., et al. Effects of tumor necrosis factor-alpha on insulin action in cultured human muscle cells. Diabetes 50 (2001) 1102-1109
40. Uysal K.T., Wiesbrock S.M., Marino M.W., et al. Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function. Nature 389 (1997) 610-614
41. Sabile A., Perlemuter G., Bono F., et al. Hepatitis C virus core protein binds to apolipoprotein AII and its secretion is modulated by fibrates. Hepatology 30 (1999) 1064-1076
42. Agnello V., Abel G., Elfahal M., et al. Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor. Proc Natl Acad Sci U S A 96 (1999) 12766-12771
43. Shi S.T., Polyak S.J., Tu H., et al. Hepatitis C virus NS5A colocalizes with the core protein on lipid droplets and interacts with apolipoproteins. Virology 292 (2002) 198-210
44. Adinolfi L.E., Gambardella M., Andreana A., et al. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 33 (2001) 1358-1364
45. Younossi Z.M., McCullough A.J., Ong J.P., et al. Obesity and non-alcoholic fatty liver disease in chronic hepatitis C. J Clin Gastroenterol 38 (2004) 705-709
46. Bellentani S., Pozzato G., Saccoccio G., et al. Clinical course and risk factors of hepatitis C virus related liver disease in the general population: report from the Dionysos study. Gut 44 (1999) 874-880
47. Chen C.M., Yoon Y.H., Yi H.Y., et al. Alcohol and hepatitis C mortality among males and females in the United States: a life table analysis. Alcohol Clin Exp Res 31 (2007) 285-292
48. Thomas D.L., Astemborski J., Rai R.M., et al. The natural history of hepatitis C virus infection: host, viral, and environmental factors. Jama 284 (2000) 450-456
49. Solis-Herruzo J.A., Perez-Carreras M., Rivas E., et al. Factors associated with the presence of nonalcoholic steatohepatitis in patients with chronic hepatitis C. Am J Gastroenterol 100 (2005) 1091-1098
50. Sanyal A.J., Campbell-Sargent C., Mirshahi F., et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 120 (2001) 1183-1192
51. Tilg H., and Diehl A.M. Cytokines in alcoholic and non-alcoholic steatohepatitis. N Engl J Med 343 20 (2000) 1467-1476
52. Konishi M., Iwasa M., Araki J., et al. Increased lipid peroxidation in patients with non-alcoholic fatty liver disease and chronic hepatitis C as measured by the plasma level of 8-isoprostane. J Gastroenterol Hepatol 21 (2006) 1821-1825
53. Par A., Roth E., Rumi Jr. G., et al. [Oxidative stress and antioxidant defense in alcoholic liver disease and chronic hepatitis C]. Orv Hetil 141 (2000) 1655-1659
54. Madan K., Bhardwaj P., Thareja S., et al. Oxidant stress and antioxidant status among patients with nonalcoholic fatty liver disease (NAFLD). J Clin Gastroenterol 40 (2006) 930-935
55. Britton R.S., and Bacon B.R. Role of free radicals in liver diseases and hepatic fibrosis. Hepatogastroenterology 41 (1994) 343-348
56. Bedossa P., Houglum K., Trautwein C., et al. Stimulation of collagen alpha 1(I) gene expression is associated with lipid peroxidation in hepatocellular injury: a link to tissue fibrosis?. Hepatology 19 (1994) 1262-1271
57. Esterbauer H., Schaur R.J., and Zollner H. Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic Biol Med 11 (1991) 81-128
58. Look M.P., Gerard A., Rao G.S., et al. Interferon/antioxidant combination therapy for chronic hepatitis C-a controlled pilot trial. Antiviral Res 43 (1999) 113-122
59. Loguercio C., Federico A., Trappoliere M., et al. The Effect of a Silybin-Vitamin E-Phospholipid Complex on Nonalcoholic Fatty Liver Disease: A Pilot Study. Dig Dis Sci 52 9 (2007) 2387-2395
60. Harrison S.A., Brunt E.M., Qazi R.A., et al. Effect of significant histologic steatosis or steatohepatitis on response to antiviral therapy in patients with chronic hepatitis C. Clin Gastroenterol Hepatol 3 (2005) 604-609
61. Romero-Gomez M., Del Mar Viloria M., Andrade R.J., et al. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology 128 (2005) 636-641
62. Bressler B.L., Guindi M., Tomlinson G., et al. High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C. Hepatology 38 (2003) 639-644
63. Giannini E., Ceppa P., and Testa R. Steatosis in chronic hepatitis C: can weight reduction improve therapeutic efficacy?. J Hepatol 35 (2001) 432-433
64. Banerjee D., Williams E.V., Ilott J., et al. Obesity predisposes to increased drainage following axillary node clearance: a prospective audit. Ann R Coll Surg Engl 83 (2001) 268-271
65. Walsh M.J., Jonsson J.R., Richardson M.M., et al. Non-response to antiviral therapy is associated with obesity and increased hepatic expression of suppressor of cytokine signalling 3 (SOCS-3) in patients with chronic hepatitis C, viral genotype 1. Gut 55 (2006) 529-535
66. Monazahian M., Bohme I., Bonk S., et al. Low density lipoprotein receptor as a candidate receptor for hepatitis C virus. J Med Virol 57 (1999) 223-229
67. Brown M.S., and Goldstein J.L. Lowering plasma cholesterol by raising LDL receptors. N Engl J Med 305 (1981) 515-517
68. Ikeda M., Abe K., Yamada M., et al. Different anti-HCV profiles of statins and their potential for combination therapy with interferon. Hepatology 44 (2006) 117-125
69. Ye J., Wang C., Sumpter Jr. R., et al. Disruption of hepatitis C virus RNA replication through inhibition of host protein geranylgeranylation. Proc Natl Acad Sci U S A 100 (2003) 15865-15870
70. Kapadia S.B., and Chisari F.V. Hepatitis C virus RNA replication is regulated by host geranylgeranylation and fatty acids. Proc Natl Acad Sci U S A 102 (2005) 2561-2566
71. O'Leary J.G., Chan J.L., McMahon C.M., et al. Atorvastatin does not exhibit antiviral activity against HCV at conventional doses: a pilot clinical trial. Hepatology 45 (2007) 895-898
72. Gopal K., Johnson T.C., Gopal S., et al. Correlation between beta-lipoprotein levels and outcome of hepatitis C treatment. Hepatology 44 (2006) 335-340
73. Hamamoto S., Uchida Y., Wada T., et al. Changes in serum lipid concentrations in patients with chronic hepatitis C virus positive hepatitis responsive or non-responsive to interferon therapy. J Gastroenterol Hepatol 20 (2005) 204-208
74. Belfort R., Harrison S.A., Brown K., et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 355 (2006) 2297-2307
75. Hourigan L.F., Macdonald G.A., Purdie D., et al. Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis. Hepatology 29 (1999) 1215-1219
76. Hickman I.J., Powell E.E., Prins J.B., et al. In overweight patients with chronic hepatitis C, circulating insulin is associated with hepatic fibrosis: implications for therapy. J Hepatol 39 (2003) 1042-1048
77. Sanyal A.J., Contos M.J., Sterling R.K., et al. Nonalcoholic fatty liver disease in patients with hepatitis C is associated with features of the metabolic syndrome. Am J Gastroenterol 98 (2003) 2064-2071
78. Liu C.J., Jeng Y.M., Chen P.L., et al. Influence of metabolic syndrome, viral genotype and antiviral therapy on superimposed fatty liver disease in chronic hepatitis C. Antivir Ther 10 (2005) 404-415
79. Mihm S., Fayyazi A., Hartmann H., et al. Analysis of histopathological manifestations of chronic hepatitis C virus infection with respect to virus genotype. Hepatology 25 (1997) 735-739
80. Clouston A.D., Jonsson J.R., Purdie D.M., et al. Steatosis and chronic hepatitis C: analysis of fibrosis and stellate cell activation. J Hepatol 34 (2001) 314-320
81. Poynard T., Ratziu V., McHutchison J., et al. Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology 38 (2003) 75-85
82. Ratziu V., Munteanu M., Charlotte F., et al. Fibrogenic impact of high serum glucose in chronic hepatitis C. J Hepatol 39 (2003) 1049-1055
83. Bugianesi E., Marchesini G., Gentilcore E., et al. Fibrosis in genotype 3 chronic hepatitis C and nonalcoholic fatty liver disease: Role of insulin resistance and hepatic steatosis. Hepatology 44 (2006) 1648-1655
84. Akuta N., Suzuki F., Tsubota A., et al. Efficacy of interferon monotherapy to 394 consecutive naive cases infected with hepatitis C virus genotype 2a in Japan: therapy efficacy as consequence of tripartite interaction of viral, host and interferon treatment-related factors. J Hepatol 37 (2002) 831-836